{
  "schema_version": "3.1.1-production",
  "doc_id": "CT-19544",
  "evaluation_id": "CT-19544",
  "extraction_date": "2022-02-02",
  "extraction_metadata": {
    "processing_version": "auto",
    "extraction_date": "2022-02-02",
    "parser": "auto",
    "annotateur_default": "auto",
    "niveau_confiance_default": 4,
    "source_files": {
      "F1": {
        "file_name": "ct_CT-19544_RIZMOIC_PIC_INS_AvisDef_CT19544.pdf",
        "type": "CT",
        "page_count": 45
      },
      "F2": {
        "file_name": "trans_1_rizmoic_02022022_transcription_ct_19544.pdf",
        "type": "TRANSCRIPTION",
        "page_count": 9
      }
    }
  },
  "template_detecte": "CT_modern",
  "section_taxonomy_version": "1.0",
  "SegmentIndex": [
    {
      "segment_id": "CT-19544_seg_01",
      "section_label_normalise": "SYNTHESE_DE_L_AVIS",
      "section_label_brut": "L’essentiel",
      "template_detecte": "CT_modern",
      "page_start": 1,
      "page_end": 1,
      "char_start": 0,
      "char_end": 500,
      "heading_text": "L’essentiel",
      "expected_fields": [
        "avis_favorable",
        "progres",
        "place_strategie"
      ],
      "routing_hint": "Introduction",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_02",
      "section_label_normalise": "MOTIF_EXAMEN",
      "section_label_brut": "Motif de l’examen",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 300,
      "heading_text": "Motif de l’examen",
      "expected_fields": [
        "indication",
        "smr",
        "asmr",
        "isp",
        "place_strategie",
        "population_cible"
      ],
      "routing_hint": "Contexte évaluation",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_03",
      "section_label_normalise": "INDICATIONS_THERAPEUTIQUES",
      "section_label_brut": "Indication",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 4,
      "char_start": 0,
      "char_end": 200,
      "heading_text": "Indication",
      "expected_fields": [
        "indication_precise"
      ],
      "routing_hint": "Indication AMM",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_04",
      "section_label_normalise": "POSOLOGIE",
      "section_label_brut": "Posologie",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 5,
      "char_start": 0,
      "char_end": 400,
      "heading_text": "Posologie",
      "expected_fields": [
        "dose",
        "populations_particulieres",
        "mode_administration"
      ],
      "routing_hint": "Posologie recommandée",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_05",
      "section_label_normalise": "BESOIN_MEDICAL",
      "section_label_brut": "Besoin médical",
      "template_detecte": "CT_modern",
      "page_start": 5,
      "page_end": 6,
      "char_start": 0,
      "char_end": 600,
      "heading_text": "Besoin médical",
      "expected_fields": [
        "description_besoin",
        "alternatives_disponibles"
      ],
      "routing_hint": "Contexte clinique",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_06",
      "section_label_normalise": "COMPARATEURS_PERTINENTS",
      "section_label_brut": "Comparateurs cliniquement pertinents",
      "template_detecte": "CT_modern",
      "page_start": 6,
      "page_end": 8,
      "char_start": 0,
      "char_end": 800,
      "heading_text": "Comparateurs cliniquement pertinents",
      "expected_fields": [
        "comparateurs_medicaments",
        "comparateurs_non_medicamenteux"
      ],
      "routing_hint": "Comparateurs HAS",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_07",
      "section_label_normalise": "ETUDES",
      "section_label_brut": "Analyse des données disponibles",
      "template_detecte": "CT_modern",
      "page_start": 9,
      "page_end": 42,
      "char_start": 0,
      "char_end": 10000,
      "heading_text": "Analyse des données disponibles",
      "expected_fields": [
        "essais_cliniques",
        "resultats_efficacite",
        "qualite_vie",
        "tolerance"
      ],
      "routing_hint": "Données cliniques",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_08",
      "section_label_normalise": "PLACE_DANS_LA_STRATEGIE",
      "section_label_brut": "Place dans la stratégie thérapeutique",
      "template_detecte": "CT_modern",
      "page_start": 42,
      "page_end": 43,
      "char_start": 0,
      "char_end": 500,
      "heading_text": "Place dans la stratégie thérapeutique",
      "expected_fields": [
        "description_place",
        "comparateurs_references"
      ],
      "routing_hint": "Conclusion place",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_09",
      "section_label_normalise": "CONCLUSIONS_CT",
      "section_label_brut": "Conclusions de la Commission",
      "template_detecte": "CT_modern",
      "page_start": 43,
      "page_end": 45,
      "char_start": 0,
      "char_end": 800,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [
        "smr",
        "asmr",
        "population_cible",
        "avis_inscription"
      ],
      "routing_hint": "Décision finale",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_1",
      "section_label_normalise": "TRANSCRIPTION",
      "section_label_brut": "Commission de Transparence - Avertissement",
      "template_detecte": "TRANSCRIPTION",
      "page_start": 1,
      "page_end": 2,
      "char_start": 0,
      "char_end": null,
      "heading_text": "AVERTISSEMENT",
      "expected_fields": [],
      "routing_hint": "Métadonnées et avertissement sur la transcription",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_2",
      "section_label_normalise": "TRANSCRIPTION",
      "section_label_brut": "Commission de Transparence - Présentation dossier",
      "template_detecte": "TRANSCRIPTION",
      "page_start": 3,
      "page_end": 4,
      "char_start": 0,
      "char_end": null,
      "heading_text": "Examen inscription : RIZMOIC",
      "expected_fields": [],
      "routing_hint": "Présentation du dossier par le chef de projet HAS",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_3",
      "section_label_normalise": "TRANSCRIPTION",
      "section_label_brut": "Commission de Transparence - Interventions experts",
      "template_detecte": "TRANSCRIPTION",
      "page_start": 5,
      "page_end": 6,
      "char_start": 0,
      "char_end": null,
      "heading_text": "Interventions Pr Bigard et Dr Blondon",
      "expected_fields": [],
      "routing_hint": "Interventions des experts sur les études et la place thérapeutique",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19544_seg_4",
      "section_label_normalise": "TRANSCRIPTION",
      "section_label_brut": "Commission de Transparence - Débats et votes",
      "template_detecte": "TRANSCRIPTION",
      "page_start": 7,
      "page_end": 9,
      "char_start": 0,
      "char_end": null,
      "heading_text": "Débats, questions et vote",
      "expected_fields": [],
      "routing_hint": "Débats entre membres, questions et vote final",
      "label_confidence": 0.95
    }
  ],
  "Identifiants_Produits_Liaison": [
    {
      "produit_nom_commercial": "RIZMOIC",
      "dci": "naldémédine",
      "titulaire_amm": "SHIONOGI",
      "code_cis": "Non renseigné",
      "code_cip13": "Non renseigné",
      "evidence": [
        {
          "field": "produit_nom_commercial",
          "f": "F1",
          "p": 1,
          "s": "RIZMOIC",
          "t": "RIZMOIC 200 microgrammes, comprimés pelliculés",
          "m": "manual",
          "c": 0.98
        },
        {
          "field": "dci",
          "f": "F1",
          "p": 1,
          "s": "naldémédine",
          "t": "naldémédine",
          "m": "manual",
          "c": 0.98
        },
        {
          "field": "titulaire_amm",
          "f": "F1",
          "p": 49,
          "s": "SHIONOGI",
          "t": "Demandeur SHIONOGI",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Evaluations_HAS": [
    {
      "evaluation_id": "CT-19544",
      "Num_avis": "CT-19544",
      "produit_nom": "RIZMOIC",
      "dci": "naldémédine",
      "type_avis": "Inscription",
      "type_avis_enum": "Inscription",
      "forme": "comprimés pelliculés",
      "dosage": "200 microgrammes",
      "indication": "Traitement de la constipation induite par les opioïdes (CIO) chez les patients adultes ayant été traités préalablement par un laxatif",
      "classe_ATC": "A06AH05",
      "pathologie": "constipation induite par les opioïdes",
      "maladie_rare": false,
      "ligne_traitement": "1ère intention",
      "ligne_traitement_enum": "1L",
      "sous_groupe_population": "patients adultes ayant été traités préalablement par un laxatif",
      "cim10_principal": "Non renseigné",
      "cim10_secondaires": [],
      "libelle_cim10": "Non renseigné",
      "source_cim10": "Non renseigné",
      "aire_therapeutique_niveau_1": "Gastro-entérologie",
      "aire_therapeutique_niveau_2": "Constipation",
      "aire_therapeutique_niveau_3": "Constipation induite par les opioïdes",
      "source_aire_therapeutique": "Déduit indication",
      "design_etude": "Etudes de phase III randomisées double-aveugle",
      "niveau_preuve_brut": "Données de phase III",
      "niveau_preuve_interprete": "Phase_III_RCT_DB",
      "besoin_medical_brut": "Partiellement couvert par les médicaments disponibles",
      "besoin_medical_interprete": "Partiellement_couvert",
      "smr": "FAIBLE",
      "smr_enum": "Faible",
      "asmr": "ASMR V",
      "asmr_enum": "V",
      "caractere_innovant_reconnu": false,
      "perte_de_chance_citee": false,
      "historique_Has_produit": "Première évaluation",
      "historique_ASMR_comparateurs": "Non renseigné",
      "concurrence_therapeutique_recente": "Non renseigné",
      "vote_unanimite": null,
      "nb_votants": 22,
      "nb_voix_pour": 22,
      "nb_voix_contre": null,
      "nb_abstentions": null,
      "date_evaluation": "2022-02-02",
      "transcription_textuelle": "Non renseigné",
      "extraits_arguments": [],
      "pathologie_categorie_enum": "Autre",
      "age_restriction_flag": false,
      "age_restriction_detail": "Adultes",
      "biomarqueur_requis": "Aucun",
      "design_enum": "Phase_III_RCT_DB",
      "gravite_patho": "Non renseigné",
      "gravite_patho_enum": [],
      "type_population_cible": "Adultes",
      "pertinence_concurrence_therapeutique": "Non renseigné",
      "evidence": [
        {
          "field": "smr",
          "f": "F1",
          "p": 3,
          "s": "SMR FAIBLE",
          "t": "SMR FAIBLE",
          "m": "manual",
          "c": 0.98
        },
        {
          "field": "asmr",
          "f": "F1",
          "p": 3,
          "s": "ASMR V",
          "t": "ASMR V",
          "m": "manual",
          "c": 0.98
        },
        {
          "field": "indication",
          "f": "F1",
          "p": 4,
          "s": "Indication",
          "t": "Traitement de la constipation induite par les opioïdes (CIO) chez les patients adultes ayant été traités préalablement par un laxatif",
          "m": "manual",
          "c": 0.98
        },
        {
          "field": "classe_ATC",
          "f": "F1",
          "p": 49,
          "s": "Code ATC",
          "t": "Code ATC A06AH05",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Essais_Cliniques": [
    {
      "essai_id": "CT-19544_essai_COMPOSE1",
      "evaluation_id": "CT-19544",
      "nom_essai": "COMPOSE-1",
      "nct_number": "NCT01965158",
      "design": "Phase III, randomisée, double-aveugle",
      "design_enum": "Phase_III_RCT_DB",
      "population_cible": "Patients adultes ayant des douleurs chroniques non-cancéreuses et constipation induite par les opioïdes",
      "comparateur_utilise": "placebo",
      "nb_patient_traitement": 274,
      "nb_patient_comparateur": 273,
      "resultat_global": "Supériorité significative vs placebo",
      "QoL_flag": false,
      "niveau_preuve": "Phase III",
      "pooling_flag": false,
      "population_dedoublée": false,
      "suivi_median_mois": 3,
      "arret_premature_flag": false,
      "duree_traitement_moyenne_mois": 3,
      "phase": "III",
      "aveugle": "Double_aveugle",
      "randomisation_flag": true,
      "randomisation_ratio": "1:1",
      "stratification_flag": true,
      "stratification_facteurs": [
        "dose d'opioïde"
      ],
      "population_analyse_principale": "ITT",
      "date_cutoff_donnees": "Non renseigné",
      "duree_suivi_prevu_mois": 3,
      "maturite_donnees": "Matures",
      "age_min_num": 18,
      "age_max_num": 80,
      "ligne_traitement_essai_enum": "Non renseigné",
      "comparateur_type_enum": "Placebo",
      "efficacite_demontree": true,
      "magnitude_effet_categorie": "Modéré",
      "maturite_pct": 100,
      "arret_premature_raison": "Non applicable",
      "arret_premature_date": "Non renseigné",
      "analyse_interimaire_plannifiee": false,
      "qol_instruments": [],
      "qol_resultats_brut": "Non renseigné",
      "qol_difference_cliniquement_pertinente": false,
      "qol_favorable": false,
      "nb_facteurs_stratification": 1,
      "nb_patients_inclus": "547",
      "nb_patients_inclus_par_pays": [],
      "date_fin_inclusion": "Non renseigné",
      "nb_analyses_intermediaire": null,
      "date_analyses_intermediares_mois": [],
      "evidence": [
        {
          "field": "nom_essai",
          "f": "F1",
          "p": 9,
          "s": "COMPOSE-1",
          "t": "COMPOSE-1 (N = 547)",
          "m": "manual",
          "c": 0.98
        },
        {
          "field": "nb_patient_traitement",
          "f": "F1",
          "p": 13,
          "s": "274 patients",
          "t": "274 patients dans le groupe naldémédine",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "essai_id": "CT-19544_essai_COMPOSE2",
      "evaluation_id": "CT-19544",
      "nom_essai": "COMPOSE-2",
      "nct_number": "NCT01993940",
      "design": "Phase III, randomisée, double-aveugle",
      "design_enum": "Phase_III_RCT_DB",
      "population_cible": "Patients adultes ayant des douleurs chroniques non-cancéreuses et constipation induite par les opioïdes",
      "comparateur_utilise": "placebo",
      "nb_patient_traitement": 277,
      "nb_patient_comparateur": 276,
      "resultat_global": "Supériorité significative vs placebo",
      "QoL_flag": false,
      "niveau_preuve": "Phase III",
      "pooling_flag": false,
      "population_dedoublée": false,
      "suivi_median_mois": 3,
      "arret_premature_flag": false,
      "duree_traitement_moyenne_mois": 3,
      "phase": "III",
      "aveugle": "Double_aveugle",
      "randomisation_flag": true,
      "randomisation_ratio": "1:1",
      "stratification_flag": true,
      "stratification_facteurs": [
        "dose d'opioïde"
      ],
      "population_analyse_principale": "ITT",
      "date_cutoff_donnees": "Non renseigné",
      "duree_suivi_prevu_mois": 3,
      "maturite_donnees": "Matures",
      "age_min_num": 18,
      "age_max_num": 80,
      "ligne_traitement_essai_enum": "Non renseigné",
      "comparateur_type_enum": "Placebo",
      "efficacite_demontree": true,
      "magnitude_effet_categorie": "Modéré",
      "maturite_pct": 100,
      "arret_premature_raison": "Non applicable",
      "arret_premature_date": "Non renseigné",
      "analyse_interimaire_plannifiee": false,
      "qol_instruments": [],
      "qol_resultats_brut": "Non renseigné",
      "qol_difference_cliniquement_pertinente": false,
      "qol_favorable": false,
      "nb_facteurs_stratification": 1,
      "nb_patients_inclus": "553",
      "nb_patients_inclus_par_pays": [],
      "date_fin_inclusion": "Non renseigné",
      "nb_analyses_intermediaire": null,
      "date_analyses_intermediares_mois": [],
      "evidence": [
        {
          "field": "nom_essai",
          "f": "F1",
          "p": 9,
          "s": "COMPOSE-2",
          "t": "COMPOSE-2 (N = 553)",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    },
    {
      "essai_id": "CT-19544_essai_COMPOSE3",
      "evaluation_id": "CT-19544",
      "nom_essai": "COMPOSE-3",
      "nct_number": "NCT01965652",
      "design": "Phase III, randomisée, double-aveugle, tolérance à long terme",
      "design_enum": "Phase_III_RCT_DB",
      "population_cible": "Patients adultes ayant des douleurs chroniques non-cancéreuses et constipation induite par les opioïdes",
      "comparateur_utilise": "placebo",
      "nb_patient_traitement": 621,
      "nb_patient_comparateur": 620,
      "resultat_global": "Profil de tolérance acceptable",
      "QoL_flag": false,
      "niveau_preuve": "Phase III",
      "pooling_flag": false,
      "population_dedoublée": false,
      "suivi_median_mois": 12,
      "arret_premature_flag": false,
      "duree_traitement_moyenne_mois": 12,
      "phase": "III",
      "aveugle": "Double_aveugle",
      "randomisation_flag": true,
      "randomisation_ratio": "1:1",
      "stratification_flag": true,
      "stratification_facteurs": [
        "dose d'opioïde"
      ],
      "population_analyse_principale": "Safety population",
      "date_cutoff_donnees": "Non renseigné",
      "duree_suivi_prevu_mois": 12,
      "maturite_donnees": "Matures",
      "age_min_num": 18,
      "age_max_num": 80,
      "ligne_traitement_essai_enum": "Non renseigné",
      "comparateur_type_enum": "Placebo",
      "efficacite_demontree": null,
      "magnitude_effet_categorie": "Non renseigné",
      "maturite_pct": 100,
      "arret_premature_raison": "Non applicable",
      "arret_premature_date": "Non renseigné",
      "analyse_interimaire_plannifiee": false,
      "qol_instruments": [],
      "qol_resultats_brut": "Non renseigné",
      "qol_difference_cliniquement_pertinente": false,
      "qol_favorable": false,
      "nb_facteurs_stratification": 1,
      "nb_patients_inclus": "1240",
      "nb_patients_inclus_par_pays": [],
      "date_fin_inclusion": "Non renseigné",
      "nb_analyses_intermediaire": null,
      "date_analyses_intermediares_mois": [],
      "evidence": [
        {
          "field": "nom_essai",
          "f": "F1",
          "p": 9,
          "s": "COMPOSE-3",
          "t": "COMPOSE-3 (N = 1 240)",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    },
    {
      "essai_id": "CT-19544_essai_COMPOSE4",
      "evaluation_id": "CT-19544",
      "nom_essai": "COMPOSE-4",
      "nct_number": "JAPIC-CTI-132340",
      "design": "Phase III, randomisée, double-aveugle",
      "design_enum": "Phase_III_RCT_DB",
      "population_cible": "Patients adultes ayant des douleurs d'origine cancéreuse et constipation induite par les opioïdes",
      "comparateur_utilise": "placebo",
      "nb_patient_traitement": 97,
      "nb_patient_comparateur": 96,
      "resultat_global": "Supériorité significative vs placebo",
      "QoL_flag": false,
      "niveau_preuve": "Phase III",
      "pooling_flag": false,
      "population_dedoublée": false,
      "suivi_median_mois": 0.5,
      "arret_premature_flag": false,
      "duree_traitement_moyenne_mois": 0.5,
      "phase": "III",
      "aveugle": "Double_aveugle",
      "randomisation_flag": true,
      "randomisation_ratio": "1:1",
      "stratification_flag": true,
      "stratification_facteurs": [],
      "population_analyse_principale": "FAS",
      "date_cutoff_donnees": "Non renseigné",
      "duree_suivi_prevu_mois": 0.5,
      "maturite_donnees": "Matures",
      "age_min_num": 20,
      "age_max_num": null,
      "ligne_traitement_essai_enum": "Non renseigné",
      "comparateur_type_enum": "Placebo",
      "efficacite_demontree": true,
      "magnitude_effet_categorie": "Majeur",
      "maturite_pct": 100,
      "arret_premature_raison": "Non applicable",
      "arret_premature_date": "Non renseigné",
      "analyse_interimaire_plannifiee": false,
      "qol_instruments": [],
      "qol_resultats_brut": "Non renseigné",
      "qol_difference_cliniquement_pertinente": false,
      "qol_favorable": false,
      "nb_facteurs_stratification": 0,
      "nb_patients_inclus": "193",
      "nb_patients_inclus_par_pays": [],
      "date_fin_inclusion": "Non renseigné",
      "nb_analyses_intermediaire": null,
      "date_analyses_intermediares_mois": [],
      "evidence": [
        {
          "field": "nom_essai",
          "f": "F1",
          "p": 9,
          "s": "COMPOSE-4",
          "t": "COMPOSE-4 (N = 193)",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    }
  ],
  "Critères_Jugement": [
    {
      "critere_id": "CT-19544_essai_COMPOSE1_crit_repondeurs",
      "essai_id": "CT-19544_essai_COMPOSE1",
      "evaluation_id": "CT-19544",
      "nom_critere": "Pourcentage de répondeurs en termes de selles spontanées",
      "nature_critere": "Substitutif",
      "unite_mesure": "%",
      "hierarchie_critere": "Principal_primaire",
      "ordre_hierarchie": 1,
      "critere_co_primaire_groupe": null,
      "condition_test": null,
      "ajustement_alpha_realise": false,
      "methode_ajustement_alpha": "Non applicable",
      "alpha_ajuste": null,
      "alpha_global_famille": 0.05,
      "nombre_tests_famille": 1,
      "test_statistique_utilise": "Chi2",
      "modele_ajuste": false,
      "facteurs_ajustement": [],
      "analyse_stratifiee": true,
      "valeur_groupe_traitement": "47,6%",
      "valeur_groupe_comparateur": "34,6%",
      "gain_absolu": "13,0%",
      "gain_absolu_num": 13.0,
      "gain_relatif": "Non renseigné",
      "gain_relatif_num": null,
      "HR_RR_OR": "Non renseigné",
      "HR_RR_OR_num": null,
      "IC95": "[4,8 ; 21,3]",
      "IC95_low_num": 4.8,
      "IC95_high_num": 21.3,
      "p_value": "p = 0,002",
      "p_value_num": 0.002,
      "unite_normalisee": "percentage",
      "type_effet": "ARD",
      "significativite_statistique": true,
      "critere_atteint": true,
      "degre_signification": "Significatif",
      "pertinence_clinique": "Modéré",
      "commentaire_has_resultat": "Non renseigné",
      "is_primary": true,
      "evidence": [
        {
          "field": "valeur_groupe_traitement",
          "f": "F1",
          "p": 16,
          "s": "130 (47,6)",
          "t": "130 (47,6)",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "critere_id": "CT-19544_essai_COMPOSE2_crit_repondeurs",
      "essai_id": "CT-19544_essai_COMPOSE2",
      "evaluation_id": "CT-19544",
      "nom_critere": "Pourcentage de répondeurs en termes de selles spontanées",
      "nature_critere": "Substitutif",
      "unite_mesure": "%",
      "hierarchie_critere": "Principal_primaire",
      "ordre_hierarchie": 1,
      "critere_co_primaire_groupe": null,
      "condition_test": null,
      "ajustement_alpha_realise": false,
      "methode_ajustement_alpha": "Non applicable",
      "alpha_ajuste": null,
      "alpha_global_famille": 0.05,
      "nombre_tests_famille": 1,
      "test_statistique_utilise": "Chi2",
      "modele_ajuste": false,
      "facteurs_ajustement": [],
      "analyse_stratifiee": true,
      "valeur_groupe_traitement": "52,5%",
      "valeur_groupe_comparateur": "33,6%",
      "gain_absolu": "18,9%",
      "gain_absolu_num": 18.9,
      "gain_relatif": "Non renseigné",
      "gain_relatif_num": null,
      "HR_RR_OR": "Non renseigné",
      "HR_RR_OR_num": null,
      "IC95": "[10,8 ; 27,0]",
      "IC95_low_num": 10.8,
      "IC95_high_num": 27.0,
      "p_value": "p < 0,0001",
      "p_value_num": 0.0001,
      "unite_normalisee": "percentage",
      "type_effet": "ARD",
      "significativite_statistique": true,
      "critere_atteint": true,
      "degre_signification": "Tres_significatif",
      "pertinence_clinique": "Modéré",
      "commentaire_has_resultat": "Non renseigné",
      "is_primary": true,
      "evidence": [
        {
          "field": "valeur_groupe_traitement",
          "f": "F1",
          "p": 16,
          "s": "145 (52,5)",
          "t": "145 (52,5)",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "critere_id": "CT-19544_essai_COMPOSE4_crit_repondeurs",
      "essai_id": "CT-19544_essai_COMPOSE4",
      "evaluation_id": "CT-19544",
      "nom_critere": "Pourcentage de répondeurs en termes de selles spontanées",
      "nature_critere": "Substitutif",
      "unite_mesure": "%",
      "hierarchie_critere": "Principal_primaire",
      "ordre_hierarchie": 1,
      "critere_co_primaire_groupe": null,
      "condition_test": null,
      "ajustement_alpha_realise": false,
      "methode_ajustement_alpha": "Non applicable",
      "alpha_ajuste": null,
      "alpha_global_famille": 0.05,
      "nombre_tests_famille": 1,
      "test_statistique_utilise": "Chi2",
      "modele_ajuste": false,
      "facteurs_ajustement": [],
      "analyse_stratifiee": false,
      "valeur_groupe_traitement": "71,1%",
      "valeur_groupe_comparateur": "34,4%",
      "gain_absolu": "36,8%",
      "gain_absolu_num": 36.8,
      "gain_relatif": "Non renseigné",
      "gain_relatif_num": null,
      "HR_RR_OR": "Non renseigné",
      "HR_RR_OR_num": null,
      "IC95": "[23,7 ; 49,9]",
      "IC95_low_num": 23.7,
      "IC95_high_num": 49.9,
      "p_value": "p < 0,0001",
      "p_value_num": 0.0001,
      "unite_normalisee": "percentage",
      "type_effet": "ARD",
      "significativite_statistique": true,
      "critere_atteint": true,
      "degre_signification": "Tres_significatif",
      "pertinence_clinique": "Majeur",
      "commentaire_has_resultat": "Non renseigné",
      "is_primary": true,
      "evidence": [
        {
          "field": "valeur_groupe_traitement",
          "f": "F1",
          "p": 24,
          "s": "71,1%",
          "t": "71,1% dans le groupe naldémédine",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Tolérance": [
    {
      "tolerance_id": "CT-19544_essai_COMPOSE1_tol",
      "evaluation_id": "CT-19544",
      "essai_id": "CT-19544_essai_COMPOSE1",
      "ae_total_pct": null,
      "ae_total_pct_comparateur": null,
      "sae_pct": null,
      "sae_pct_comparateur": null,
      "discontinuations_ae_pct": null,
      "discontinuations_ae_pct_comparateur": null,
      "deaths_ae_n": null,
      "deaths_ae_n_comparateur": null,
      "sae_data_available": false,
      "sae_superieur_comparateur": null,
      "deaths_reported": false,
      "EI_graves_detailles": [],
      "EI_frequents_detailles": [],
      "ei_grade_max": "Non renseigné",
      "deces_detailles": [],
      "signal_securite_flag": false,
      "signal_ansm_flag": false,
      "EI_graves": "Non renseigné",
      "EI_frequents": "Non renseigné",
      "deces": "Non renseigné",
      "signal_securite": "Non renseigné",
      "evidence": [],
      "_meta": {}
    },
    {
      "tolerance_id": "CT-19544_essai_COMPOSE3_tol",
      "evaluation_id": "CT-19544",
      "essai_id": "CT-19544_essai_COMPOSE3",
      "ae_total_pct": 68.4,
      "ae_total_pct_comparateur": 72.1,
      "sae_pct": 9.7,
      "sae_pct_comparateur": 11.8,
      "discontinuations_ae_pct": 6.3,
      "discontinuations_ae_pct_comparateur": 5.8,
      "deaths_ae_n": 4,
      "deaths_ae_n_comparateur": 4,
      "sae_data_available": true,
      "sae_superieur_comparateur": false,
      "deaths_reported": true,
      "EI_graves_detailles": [],
      "EI_frequents_detailles": [
        {
          "ei_terme": "Douleurs abdominales",
          "grade": "Tous grades",
          "incidence_pct_traitement": 8.2,
          "incidence_pct_comparateur": 3.1,
          "evidence": []
        },
        {
          "ei_terme": "Diarrhée",
          "grade": "Tous grades",
          "incidence_pct_traitement": 11.0,
          "incidence_pct_comparateur": 5.3,
          "evidence": []
        }
      ],
      "ei_grade_max": "3-4",
      "deces_detailles": [],
      "signal_securite_flag": false,
      "signal_ansm_flag": false,
      "EI_graves": "Non renseigné",
      "EI_frequents": "Non renseigné",
      "deces": "Non renseigné",
      "signal_securite": "Non renseigné",
      "evidence": [
        {
          "field": "sae_pct",
          "f": "F1",
          "p": 33,
          "s": "9,7%",
          "t": "9,7% dans le groupe naldémédine",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Comparateurs_Essai": [
    {
      "comparateur_id": "CT-19544_essai_COMPOSE1_comp_01",
      "essai_id": "CT-19544_essai_COMPOSE1",
      "nom_comparateur": "placebo",
      "type_comparateur": "Placebo",
      "comparateur_standard_soin": "Non applicable",
      "comparateur_standard_enum": "Placebo",
      "evidence": [
        {
          "field": "nom_comparateur",
          "f": "F1",
          "p": 9,
          "s": "placebo",
          "t": "comparaison au placebo",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19544_essai_COMPOSE2_comp_01",
      "essai_id": "CT-19544_essai_COMPOSE2",
      "nom_comparateur": "placebo",
      "type_comparateur": "Placebo",
      "comparateur_standard_soin": "Non applicable",
      "comparateur_standard_enum": "Placebo",
      "evidence": [
        {
          "field": "nom_comparateur",
          "f": "F1",
          "p": 9,
          "s": "placebo",
          "t": "comparaison au placebo",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19544_essai_COMPOSE3_comp_01",
      "essai_id": "CT-19544_essai_COMPOSE3",
      "nom_comparateur": "placebo",
      "type_comparateur": "Placebo",
      "comparateur_standard_soin": "Non applicable",
      "comparateur_standard_enum": "Placebo",
      "evidence": [
        {
          "field": "nom_comparateur",
          "f": "F1",
          "p": 9,
          "s": "placebo",
          "t": "comparaison au placebo",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19544_essai_COMPOSE4_comp_01",
      "essai_id": "CT-19544_essai_COMPOSE4",
      "nom_comparateur": "placebo",
      "type_comparateur": "Placebo",
      "comparateur_standard_soin": "Non applicable",
      "comparateur_standard_enum": "Placebo",
      "evidence": [
        {
          "field": "nom_comparateur",
          "f": "F1",
          "p": 9,
          "s": "placebo",
          "t": "comparaison au placebo",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Comparateurs_HAS": [
    {
      "comparateur_id": "CT-19544_compHAS_01",
      "evaluation_id": "CT-19544",
      "nom_comparateur_HAS": "MOVENTIG (naloxégol)",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Alternative dans la stratégie",
      "famille_comparateur": "Antagoniste_opioïde",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 7,
          "s": "MOVENTIG",
          "t": "MOVENTIG (naloxégol par voie orale)",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "comparateur_id": "CT-19544_compHAS_02",
      "evaluation_id": "CT-19544",
      "nom_comparateur_HAS": "RELISTOR (méthylnaltrexone bromure)",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Alternative dans la stratégie",
      "famille_comparateur": "Antagoniste_opioïde",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 7,
          "s": "RELISTOR",
          "t": "RELISTOR (méthylnaltrexone bromure)",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Arguments_Decisionnels": [
    {
      "argument_id": "CT-19544_arg_TRANS_1",
      "evaluation_id": "CT-19544",
      "source_argument": "TRANS",
      "categorie_argument": "Efficacité",
      "direction_argument": "Neutre",
      "description": "Efficacité démontrée vs placebo dans les études COMPOSE, avec un gain modeste d'environ 1 selle/semaine chez les patients non cancéreux et 2,5 selles/semaine chez les cancéreux.",
      "extrait_textuel": "Quand on les met sous ce traitement pendant 12 semaines, on va gagner une selle. Ce n'est pas formidable.",
      "importance_argument": "Important",
      "niveau_incertitude": "Faible",
      "intervenant": "Pr Bigard",
      "moment_debat": "Intervention expert",
      "impact_decision": "Contributeur",
      "page_source": "Page 5",
      "section_source": "Interventions experts",
      "evidence": [
        {
          "field": "description",
          "f": "F1",
          "p": 5,
          "s": "CT-19544",
          "t": "Quand on les met sous ce traitement pendant 12 semaines, on va gagner une selle. Ce n'est pas formidable.",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "argument_id": "CT-19544_arg_TRANS_2",
      "evaluation_id": "CT-19544",
      "source_argument": "TRANS",
      "categorie_argument": "Population",
      "direction_argument": "Neutre",
      "description": "Données disponibles pour deux populations distinctes : patients avec douleurs non cancéreuses (états-Unis) et patients cancéreux (Japon), mais transposabilité limitée.",
      "extrait_textuel": "L'étude sur les populations des douleurs chroniques non-cancéreuses s'est faite essentiellement aux États-Unis. C'est une population très particulière.",
      "importance_argument": "Modéré",
      "niveau_incertitude": "Modérée",
      "intervenant": "Pr Bigard",
      "moment_debat": "Intervention expert",
      "impact_decision": "Contributeur",
      "page_source": "Page 5",
      "section_source": "Interventions experts",
      "evidence": [
        {
          "field": "description",
          "f": "F1",
          "p": 5,
          "s": "CT-19544",
          "t": "L'étude sur les populations des douleurs chroniques non-cancéreuses s'est faite essentiellement aux États-Unis. C'est une population très particulière.",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "argument_id": "CT-19544_arg_TRANS_3",
      "evaluation_id": "CT-19544",
      "source_argument": "TRANS",
      "categorie_argument": "Comparaison",
      "direction_argument": "Neutre",
      "description": "RIZMOIC a un dossier plus complet que MOVENTIG (inclut des patients cancéreux), mais efficacité similaire; pas de comparaison directe entre les médicaments.",
      "extrait_textuel": "Le dossier est meilleur que le dossier précédent, le dossier MOVENTIG, mais il démontre la même chose.",
      "importance_argument": "Important",
      "niveau_incertitude": "Faible",
      "intervenant": "Pr Bigard",
      "moment_debat": "Intervention expert",
      "impact_decision": "Contributeur",
      "page_source": "Page 6",
      "section_source": "Interventions experts",
      "evidence": [
        {
          "field": "description",
          "f": "F1",
          "p": 6,
          "s": "CT-19544",
          "t": "Le dossier est meilleur que le dossier précédent, le dossier MOVENTIG, mais il démontre la même chose.",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "argument_id": "CT-19544_arg_TRANS_4",
      "evaluation_id": "CT-19544",
      "source_argument": "TRANS",
      "categorie_argument": "Place_thérapeutique",
      "direction_argument": "Neutre",
      "description": "RELISTOR a un SMR important et ASMR IV en soins palliatifs, mais RIZMOIC et MOVENTIG ont des SMR faibles et ASMR V; justification basée sur la population et la voie d'administration.",
      "extrait_textuel": "Le RELISTOR est souvent assez mal classé dans les recommandations internationales. En France, on n'a du RELISTOR que par voie sous-cutanée, donc c'est différent.",
      "importance_argument": "Important",
      "niveau_incertitude": "Faible",
      "intervenant": "Pr Bigard",
      "moment_debat": "Intervention expert",
      "impact_decision": "Contributeur",
      "page_source": "Page 7",
      "section_source": "Débats et votes",
      "evidence": [
        {
          "field": "description",
          "f": "F1",
          "p": 7,
          "s": "CT-19544",
          "t": "Le RELISTOR est souvent assez mal classé dans les recommandations internationales. En France, on n'a du RELISTOR que par voie sous-cutanée, donc c'est différent.",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "argument_id": "CT-19544_arg_TRANS_5",
      "evaluation_id": "CT-19544",
      "source_argument": "TRANS",
      "categorie_argument": "Données insuffisantes",
      "direction_argument": "Défavorable",
      "description": "Manque de données robustes sur la qualité de vie et données manquantes importantes dans les études.",
      "extrait_textuel": "On manque aussi de données de qualité de vie, ce qui est fondamental dans ce type d'études.",
      "importance_argument": "Modéré",
      "niveau_incertitude": "Modérée",
      "intervenant": "Dr Blondon",
      "moment_debat": "Intervention expert",
      "impact_decision": "Contributeur",
      "page_source": "Page 8",
      "section_source": "Débats et votes",
      "evidence": [
        {
          "field": "description",
          "f": "F1",
          "p": 8,
          "s": "CT-19544",
          "t": "On manque aussi de données de qualité de vie, ce qui est fondamental dans ce type d'études.",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "argument_id": "CT-19544_arg_TRANS_6",
      "evaluation_id": "CT-19544",
      "source_argument": "TRANS",
      "categorie_argument": "Procédural",
      "direction_argument": "Neutre",
      "description": "Vote de la commission : 22 voix pour absence d'ISP, 22 voix pour SMR faible, 22 voix pour ASMR V.",
      "extrait_textuel": "Nous avons 22 voix pour l'absence d'ISP, 22 voix pour un SMR faible, 22 voix pour une ASMR V.",
      "importance_argument": "Majeur",
      "niveau_incertitude": "Faible",
      "intervenant": "Mme Gattulli",
      "moment_debat": "Vote",
      "impact_decision": "Contributeur_majeur",
      "page_source": "Page 9",
      "section_source": "Débats et votes",
      "evidence": [
        {
          "field": "description",
          "f": "F1",
          "p": 9,
          "s": "CT-19544",
          "t": "Nous avons 22 voix pour l'absence d'ISP, 22 voix pour un SMR faible, 22 voix pour une ASMR V.",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Données_Contexte": {
    "contexte_id": "CT-19544_ctx",
    "evaluation_id": "CT-19544",
    "ISP": "Pas d’impact supplémentaire attendu sur la santé publique",
    "acces_precoce": "Aucun",
    "date_debut_acces_precoce": "Non renseigné",
    "date_fin_acces_precoce": "Non renseigné",
    "duree_acces_precoce_mois": null,
    "nombre_patients_acces_precoce": null,
    "conditions_arret_acces_precoce": "Non renseigné",
    "ISP_flag": false,
    "ISP_categorie": "Pas_ISP",
    "type_acces_precoce_enum": "Aucun",
    "statut_reglementaire_ema": "AMM_standard",
    "date_AMM_ema": "2019-02-18",
    "date_avis_chmp": "Non renseigné",
    "innovation_therapeutique_ema": false,
    "designation_orpheline_ema": false,
    "prime_ema": false,
    "obligations_post_amm": [],
    "echeance_reexamen_amm": "Non renseigné",
    "nb_obligations_post_amm": 0,
    "evaluation_internationale": "Oui",
    "pays_evaluations": [
      "Etats-Unis",
      "Royaume-Uni",
      "Allemagne",
      "Espagne",
      "Italie"
    ],
    "decisions_internationales": [
      {
        "pays": "Etats-Unis",
        "organisme": "FDA",
        "decision": "Recommended",
        "date_decision": "Non renseigné",
        "reference": "Non renseigné",
        "evidence": []
      }
    ],
    "nb_decisions_internationales": 1,
    "RDCR": "Non renseigné",
    "RDCR_num": null,
    "RDCR_intervalle": null,
    "RDCR_vs_seuil": "Non_applicable",
    "model_type": "Non renseigné",
    "perspective": "Non renseigné",
    "horizon_annees": null,
    "horizon_justification": "Non renseigné",
    "discount_rate_costs": null,
    "discount_rate_qalys": null,
    "DSA_flag": null,
    "PSA_flag": null,
    "scenario_analyses": [],
    "major_reserves": [],
    "nb_reserves_majeures": null,
    "impact_budgetaire_prevu": "Non renseigné",
    "impact_budgetaire_annee_1": null,
    "impact_budgetaire_annee_5": null,
    "impact_budgetaire_horizon": null,
    "hypothese_population_cible": null,
    "hypothese_penetration_marche_pct": null,
    "reserves_impact_budgetaire": [],
    "reserves_majeures": false,
    "population_cible_france": "Approximativement 801 480 patients",
    "population_cible_nombre": 801480,
    "population_cible_intervalle": null,
    "source_estimation_population": "Extrapolation",
    "incertitude_population": "Modérée",
    "population_cible_mediane": 801480,
    "suivi_post_inscription": false,
    "nature_suivi_post_inscription": "Non renseigné",
    "delai_suivi_mois": null,
    "delai_suivi_justification": "Non renseigné",
    "conditions_suivi": "Non renseigné",
    "echeance_suivi": "Non renseigné",
    "impact_si_non_realise": "Non renseigné",
    "delai_soumission_dossier": "Non renseigné",
    "delai_complement_demande": false,
    "dates_complement_demande": [],
    "delai_audition": false,
    "date_audition": "Non renseigné",
    "nb_total_reserves": null,
    "nb_total_reserves_mineures": null,
    "nb_totales_reserves_importantes": null,
    "nb_totales_reserves_majeures": null,
    "SMR_avant_audition_enum": "Non_renseigné",
    "SMR_apres_audition_enum": "Non_renseigné",
    "ASMR_avant_audition_enum": "Non_renseigné",
    "ASMR_après_audition_enum": "Non_renseigné",
    "type_critère_justification": "Non renseigné",
    "valeur_critère": "Non renseigné",
    "impact_décision": "Non renseigné",
    "estimation_mesure_impact": "Non renseigné",
    "evidence": [
      {
        "field": "date_AMM_ema",
        "f": "F1",
        "p": 4,
        "s": "18/02/2019",
        "t": "L’AMM a été octroyée selon la procédure européenne centralisée en date du 18/02/2019",
        "m": "manual",
        "c": 0.98
      }
    ],
    "_meta": {}
  },
  "Données_Textuelles": {
    "evaluation_id": "CT-19544",
    "texte_brut": "Non renseigné",
    "embedding": null,
    "evidence": []
  },
  "SMR_ASMR_Par_Indication": [
    {
      "smr_asmr_id": "CT-19544_smrasmr_01",
      "evaluation_id": "CT-19544",
      "indication_precise": "Traitement de la constipation induite par les opioïdes (CIO) chez les patients adultes ayant été traités préalablement par un laxatif",
      "smr": "FAIBLE",
      "asmr": "ASMR V",
      "smr_revendique": "Non renseigné",
      "asmr_revendique": "Non renseigné",
      "asmr_revendique_enum": "Non_renseigné",
      "justification_decisionnelle": "Non renseigné",
      "population_cible_indication": "Patients adultes atteints d'une constipation induite par les opioïdes ayant été préalablement traités par laxatifs",
      "ligne_traitement_indication": "1ère intention",
      "comparateurs_references_indication": "MOVENTIG, RELISTOR",
      "comparateur_id_HAS": [
        "CT-19544_compHAS_01",
        "CT-19544_compHAS_02"
      ],
      "indication_structuree": {
        "ligne_traitement": "1L",
        "biomarqueur": "Aucun",
        "stade": "Non renseigné",
        "population_age": "Adultes"
      },
      "gain_survie_cite": false,
      "qol_cite": false,
      "tolerance_acceptable": true,
      "evidence_robustesse": "Modérée",
      "niveau_confiance_annotation": 4,
      "annotateur": "auto",
      "evidence": [
        {
          "field": "smr",
          "f": "F1",
          "p": 3,
          "s": "SMR FAIBLE",
          "t": "SMR FAIBLE",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    }
  ],
  "Posologie_Par_Indication": [
    {
      "posologie_id": "CT-19544_poso_01",
      "evaluation_id": "CT-19544",
      "smr_asmr_id": "CT-19544_smrasmr_01",
      "indication": "Traitement de la constipation induite par les opioïdes (CIO) chez les patients adultes ayant été traités préalablement par un laxatif",
      "population_cible": "Patients adultes",
      "posologie_source": "texte_avis",
      "posologie_resumee_brut": "200 microgrammes une fois par jour",
      "phases": [
        {
          "phase_nom": "Initiation",
          "cycle_length_days": null,
          "dose_expression": {
            "basis": "fixe",
            "value": "200",
            "unite_dose": "microgrammes"
          },
          "frequence": {
            "type": "qxj",
            "dose_days_in_cycle": [
              1
            ],
            "interval_days": 1
          },
          "voie_administration": "orale",
          "expected_phase_duration_days": null
        }
      ],
      "ajustements_poso_brut": "Aucun ajustement posologique n’est nécessaire chez les patients âgés de plus de 65 ans. Insuffisance rénale et hépatique légère/modérée sans ajustement.",
      "commentaires": "Peut être pris à tout moment de la journée, avec ou sans laxatif.",
      "evidence": [
        {
          "field": "posologie_resumee_brut",
          "f": "F1",
          "p": 4,
          "s": "200 microgrammes",
          "t": "La dose recommandée de naldémédine est de 200 microgrammes (un comprimé) une fois par jour",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    }
  ],
  "Timeline_Evenements": [
    {
      "event_id": "CT-19544_event_AMM_01",
      "evaluation_id": "CT-19544",
      "event_type": "AMM_EMA_DECISION",
      "event_date": "2019-02-18",
      "detail_brut": "AMM octroyée selon la procédure européenne centralisée",
      "source_doc": "F1",
      "detail_type_specifique": "AMM standard",
      "acteurs_impliques": [
        "EMA",
        "SHIONOGI"
      ],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 4,
          "s": "18/02/2019",
          "t": "L’AMM a été octroyée selon la procédure européenne centralisée en date du 18/02/2019",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    },
    {
      "event_id": "CT-19544_event_CT_01",
      "evaluation_id": "CT-19544",
      "event_type": "ADOPTION_CT",
      "event_date": "2022-02-02",
      "detail_brut": "Avis adopté par la Commission de la Transparence",
      "source_doc": "F1",
      "detail_type_specifique": "Avis définitif",
      "acteurs_impliques": [
        "Commission de la Transparence"
      ],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 1,
          "s": "02 FEVRIER 2022",
          "t": "AVIS 02 FEVRIER 2022",
          "m": "manual",
          "c": 0.98
        }
      ],
      "_meta": {}
    }
  ],
  "Timeline_Delais": {
    "evaluation_id": "CT-19544",
    "delai_amm_ct_jours": 1080,
    "delai_transcription_ct_jours": null,
    "delai_audition_ct_jours": null,
    "complement_demande_mentionne": false,
    "audition_realisee": false,
    "evidence": [],
    "_meta": {}
  },
  "Features_Modele": {
    "evaluation_id": "CT-19544",
    "is_orphan": false,
    "classe_ATC_l2": "A06",
    "aire_therapeutique": "Gastro-entérologie",
    "type_avis_enum": "Inscription",
    "innovation_reconnue": false,
    "perte_de_chance_citee": false,
    "ligne_traitement_num": 1,
    "is_rct": true,
    "n_essais": 4,
    "n_rct": 4,
    "presence_qol": false,
    "effet_principal_magnitude_num": 13.0,
    "critere_principal_dur": false,
    "suivi_median_mois_max": 12,
    "sae_pct_num": 9.7,
    "discontinuations_pct_num": 6.3,
    "critere_principal_description": "Pourcentage de répondeurs en termes de selles spontanées",
    "p_value_log10": 2.69897,
    "ceesp_present": false,
    "rdcr_num": null,
    "rdcr_log": null,
    "impact_budget_cat": "Non renseigné",
    "reserves_majeures": false,
    "nb_reserves_majeures": 0,
    "vote_unanimite": null,
    "nb_votants": null,
    "voix_pour_pct": null,
    "association_patient_intervenue": false,
    "comparateur_placebo": true,
    "comparateur_soc": true,
    "nb_clockstops": 0,
    "annee_ct": 2022,
    "trimestre_ct": 1,
    "template_ere": "CT_modern",
    "missingness_indicators": "Non renseigné",
    "_meta": {}
  },
  "Relations": [
    {
      "src_type": "EVAL_HAS_TRIAL",
      "src_id": "CT-19544",
      "tgt_type": "TRIAL",
      "tgt_id": "CT-19544_essai_COMPOSE1",
      "label": "EVAL_HAS_TRIAL"
    },
    {
      "src_type": "EVAL_HAS_TRIAL",
      "src_id": "CT-19544",
      "tgt_type": "TRIAL",
      "tgt_id": "CT-19544_essai_COMPOSE2",
      "label": "EVAL_HAS_TRIAL"
    },
    {
      "src_type": "EVAL_HAS_TRIAL",
      "src_id": "CT-19544",
      "tgt_type": "TRIAL",
      "tgt_id": "CT-19544_essai_COMPOSE3",
      "label": "EVAL_HAS_TRIAL"
    },
    {
      "src_type": "EVAL_HAS_TRIAL",
      "src_id": "CT-19544",
      "tgt_type": "TRIAL",
      "tgt_id": "CT-19544_essai_COMPOSE4",
      "label": "EVAL_HAS_TRIAL"
    },
    {
      "src_type": "TRIAL_HAS_CRIT",
      "src_id": "CT-19544_essai_COMPOSE1",
      "tgt_type": "CRIT",
      "tgt_id": "CT-19544_essai_COMPOSE1_crit_repondeurs",
      "label": "TRIAL_HAS_CRIT"
    },
    {
      "src_type": "TRIAL_HAS_CRIT",
      "src_id": "CT-19544_essai_COMPOSE2",
      "tgt_type": "CRIT",
      "tgt_id": "CT-19544_essai_COMPOSE2_crit_repondeurs",
      "label": "TRIAL_HAS_CRIT"
    },
    {
      "src_type": "TRIAL_HAS_CRIT",
      "src_id": "CT-19544_essai_COMPOSE4",
      "tgt_type": "CRIT",
      "tgt_id": "CT-19544_essai_COMPOSE4_crit_repondeurs",
      "label": "TRIAL_HAS_CRIT"
    }
  ],
  "Annotation_View": []
}